Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Over the past 20 years, the role of “screening” as a mechanism for early diagnosis of several types of cancer (and other diseases) has become a high-profile and emotional issue in which the value of accurate data has often been swamped by media hype and the claims of specific interest groups. This is true for [...]
Filed under: Diagnosis, Risk | Tagged: Diagnosis, expectation, percention, reality, risk, screening | Leave a Comment »
In February this year we reported initial 4- and 5-year follow-up data from two US-based research teams on the use of stereotactic body radiation therapy (SBRT or CyberKnife radiation) as a treatment for prostate cancer. A new study from a Korean research group appears to confirm the earlier findings.
Filed under: Diagnosis, Management, Treatment | Tagged: body, localized, outcome, SBRT, stereotactic | 3 Comments »
A recent article in the Cleveland Clinic Journal of Medicine provides a summary of the way three leading specialists at this institution approach the diagnosis and management of localized prostate cancer today.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, localized, Treatment | Leave a Comment »
While there is general consensus that exercise helps to minimize the impact of androgen deprivation therapy (ADT) on body composition, fitness, and other factors, there is limted evidence from clinical trials about the specific types of exercise that may be of greatest value.
Filed under: Living with Prostate Cancer, Management | Tagged: aerobic, body, composition, exercise, resistance | 1 Comment »
What goes into the making of “a good doctor” is an underlying issue in many of the comments and observations that get posted on this and other, primarily patient-focused web sites. An article in this week’s issue of The Lancet deals with this issue head on, and in a very readable manner.
Filed under: Uncategorized | Leave a Comment »
Finland was a major participant in the European Randomized Study of Screening for Prostate Cancer (ERSPC). It is therefore useful to get insight into how the Finnish medical profession thought about screening for prostate cancer over the time period when this trial was being carried out
Filed under: Uncategorized | 7 Comments »
The full text of a recent article having the above title offers a good (if perhaps not perfect), reasonably current overview of issues related to PSA testing for prostate cancer and appeared recently in a supplement to the Canadian Journal of Urology.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Management, outcome, PSA, testing | 1 Comment »
According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: avanafil, ED, erctile dysfunction, inhibitor, PDE5 | Leave a Comment »
A new study based on data from nearly 500 patients gives us some insight into how a selected group of men less than 50 years of age were thinking about treatment for prostate cancer between 2001 and 2005. Whether one would get the same results for a similar group of patient diagnosed today is a good [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: choice, decision-making, influence, option, young | 2 Comments »
Over the years, a variety of studies have demonstrated a possible impact of aspirin and other non-steroidal anti-inflammatory agents or NSAIDs (e.g., ibuprofen, COX-2 inhibitors) on risk for prostate cancer. (See, for example, this report from late in 2010.)
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: acetaminophen, Prevention, risk | 3 Comments »
One of the posters to be presented at the upcoming annual meeting of the American Society of Clinical Oncology offers an interesting model permitting replicative estimation of the numbers of patients living with different clinical stages of prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: clinical status, epidemiology, prevalence, stage | 4 Comments »
An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer.
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hypogonadism, risk, serum, T, testosterone | Leave a Comment »
A newly published article, available on-line in the journal Prostate Cancer and Prostatic Diseases, shows that tissues from prostate biopsies from black men express higher levels of biomarkers for aggressive disease than do tissues from prostate biopsies taken from white men.
Filed under: Diagnosis, Risk | Tagged: aggressive, biomarker, black, risk, white | Leave a Comment »
A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer.
Filed under: Drugs in development, Management | Tagged: AdV-tk, gene suicide, immunotherapy, localized, ProstAtak, vaccine, valacyclovir | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site